Document Detail

Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity.
MedLine Citation:
PMID:  20889152     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to investigate gonadal-protective properties of thalidomide in a mouse model of chemotherapy-induced ovarian failure. Administration of thalidomide before alkylating chemotherapy preserved ovarian follicles and lead to the resumption of normal estrous cyclicity.
Melanie E Ochalski; Jennifer J Shuttleworth; Tianjiao Chu; Kyle E Orwig
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Fertility and sterility     Volume:  95     ISSN:  1556-5653     ISO Abbreviation:  Fertil. Steril.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-24     Completed Date:  2011-02-28     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  0372772     Medline TA:  Fertil Steril     Country:  United States    
Other Details:
Languages:  eng     Pagination:  819-22     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Magee-Womens Research Institute, Pittsburgh, Pennsylvania 15213, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects*,  therapeutic use
Cell Count
Cytoprotection / drug effects
Disease Models, Animal
Drug Evaluation, Preclinical
Gonads / drug effects,  pathology
Mice, Inbred C57BL
Ovary / drug effects*,  pathology
Primary Ovarian Insufficiency / chemically induced*,  pathology,  prevention & control*
Thalidomide / administration & dosage,  therapeutic use*
Grant Support
AG024992/AG/NIA NIH HHS; HD008610/HD/NICHD NIH HHS; HD055475/HD/NICHD NIH HHS; R01 AG024992/AG/NIA NIH HHS; R01 AG024992-05/AG/NIA NIH HHS; R01 HD055475/HD/NICHD NIH HHS; R01 HD055475-02/HD/NICHD NIH HHS; R01 HD055475-03/HD/NICHD NIH HHS; R01 RR018500/RR/NCRR NIH HHS; R01 RR018500-04/RR/NCRR NIH HHS; R01 RR018500-05/RR/NCRR NIH HHS; R21 HD061289/HD/NICHD NIH HHS; RR018500/RR/NCRR NIH HHS; U54-HD28934/HD/NICHD NIH HHS
Reg. No./Substance:
0/Angiogenesis Inhibitors; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hypertension and hematologic parameters in a community near a uranium processing facility.
Next Document:  Migraines and ovarian hyperstimulation syndrome: a dopamine connection.